Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABPI Welcomes Amended Legislation On Curbing Excessive Unbranded Drug Prices

Executive Summary

Newly passed UK legislation gives the government powers to curb pricing of unbranded generics when market forces fail. The Association of the British Pharmaceutical Industry has welcomed amendments to draft legislation that have addressed its concerns over onerous requirements.

You may also be interested in...



Rash of Generic Price Hikes Pushes UK Health Dept Into Action

Huge hikes in the prices of some generic medicines in the past year have forced the UK health authorities to offer many more “concessionary prices” to pharmacists to ensure continuity of supply and to seek alternative sources of some products. Legislation is due to take effect shortly that will give the government more powers to control generic prices.

Rash of Generic Price Hikes Pushes UK Health Dept Into Action

Huge hikes in the prices of some generic medicines in the past year have forced the UK health authorities to offer many more “concessionary prices” to pharmacists to ensure continuity of supply and to seek alternative sources of some products. Legislation is due to take effect shortly that will give the government more powers to control generic prices.

‘Excessive Pricing’ Inquiry Widens As EC’s First Antitrust Price Probe Targets Aspen Pharma

The litany of complaints against pharmaceutical companies for imposing “excessive” prices on generic drugs is growing after the European Commission decided to pursue Aspen Pharma over price rises imposed on a range of anticancer products it acquired from GSK.

Related Content

Topics

UsernamePublicRestriction

Register

PS120579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel